Antiviral – Idenix

Antiviral work helps Idenix buck biotech stock trend There’s at least one bit of bright biotech news amid all the economic ugliness. Cambridge-based Idenix Pharmaceuticals (Nasdaq: IDIX) ended the year with its stock price up 114 percent, compared with the biotech industry that overall by one measure — an analysis by the Biotechnology Industry Organization — was down by a … [Read more...]